Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABVC
stocks logo

ABVC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
0.00
-100%
-0.500
-66.67%
Estimates Revision
Stock Price
Go Down
down Image
-4.53%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for ABVC Biopharma Inc (ABVC.O) is -0.55, compared to its 5-year average forward P/E of -5.07. For a more detailed relative valuation and DCF analysis to assess ABVC Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.07
Current PE
-0.55
Overvalued PE
2.38
Undervalued PE
-12.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
122.65
Current PS
0.00
Overvalued PS
410.16
Undervalued PS
-164.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ABVC News & Events

Events Timeline

(ET)
2024-12-11
05:37:58
ABVC BioPharma receives $200,000 cash payment from OncoX
select
2024-11-14 (ET)
2024-11-14
08:03:15
ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year
select
2024-10-22 (ET)
2024-10-22
08:48:07
ABVC BioPharma receives $50,000 in incremental licensing fees
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
09-24Yahoo Finance
ABVC BioPharma, Inc. (ABVC) Sees 103% Increase in Assets, Preparing for Phase III Trials of Depression Treatments

  • Overview of ABVC BioPharma: ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botanically derived therapeutics for various medical conditions, including Major Depressive Disorder and oncology-related diseases.

  • Financial Performance and Pipeline Progress: The company reported significant financial growth, with a 103% increase in assets and upcoming Phase III trials for its leading drug candidates, while also noting that certain AI stocks may present better investment opportunities.

[object Object]
Preview
9.5
08-14NASDAQ.COM
Abvc BioPharma Doubles Assets in Q2

  • Financial Performance: Abvc BioPharma reported a significant increase in total assets to $16.2 million, up 103% from the previous year, alongside improved shareholders' equity and a narrower loss per share of $(0.13) for Q2 2025, although no revenue was reported for the quarter.

  • Operational Updates: The company provided updates on its clinical pipeline and partnerships but did not offer specific forward guidance or details on trial timelines, focusing instead on asset growth and licensing agreements expected to generate revenue in Q3 2025.

[object Object]
Preview
9.0
2024-12-19Newsfilter
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

  • ABVC BioPharma's New Treatment: ABVC BioPharma is developing ABV-1504, a treatment derived from Radix Polygala, as a safer alternative for Major Depressive Disorder (MDD) and ADHD following the discontinuation of Prozac due to side effect concerns. The drug has completed Phase II trials and is moving towards Phase III.

  • Market Growth Potential: The global markets for MDD and ADHD treatments are projected to grow significantly, with MDD expected to reach $14.96 billion by 2032 and ADHD treatments anticipated to increase to $15.23 billion in the same timeframe, highlighting the demand for innovative and safer mental health solutions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ABVC Biopharma Inc (ABVC) stock price today?

The current price of ABVC is 2.53 USD — it has decreased -1.56 % in the last trading day.

arrow icon

What is ABVC Biopharma Inc (ABVC)'s business?

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.

arrow icon

What is the price predicton of ABVC Stock?

Wall Street analysts forecast ABVC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ABVC Biopharma Inc (ABVC)'s revenue for the last quarter?

ABVC Biopharma Inc revenue for the last quarter amounts to 795.95K USD, increased 104.47 % YoY.

arrow icon

What is ABVC Biopharma Inc (ABVC)'s earnings per share (EPS) for the last quarter?

ABVC Biopharma Inc. EPS for the last quarter amounts to -0.05 USD, increased 66.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for ABVC Biopharma Inc (ABVC)'s fundamentals?

The market is revising No Change the revenue expectations for ABVC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -4.53%.
arrow icon

How many employees does ABVC Biopharma Inc (ABVC). have?

ABVC Biopharma Inc (ABVC) has 16 emplpoyees as of December 05 2025.

arrow icon

What is ABVC Biopharma Inc (ABVC) market cap?

Today ABVC has the market capitalization of 61.48M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free